Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67<10%.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Cwikla J
Authors: Ćwikła J, Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Pałucki J, Roszkowska-Purska K,
Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Lanreotide AG systemic therapy,
#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN
Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Ćwikla J
Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Cichocki A, Roszkowska-Purska K, Dobkowski P,
Introduction: SSA are the first line therapy in well differentiated pNET
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Kolasińska-Ćwikla A
Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Bednarczuk T, Pałucki J, Roszkowska-Purska K,
Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Octreotide LAR therapy,
#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs
Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Kolasinska-Cwikla A
Authors: Kolasińska-Ćwikła A, Cwikła J, Bodei L, Sankowski A, Drozdov I,